|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US4326525A
(en)
|
1980-10-14 |
1982-04-27 |
Alza Corporation |
Osmotic device that improves delivery properties of agent in situ
|
|
US5364620A
(en)
|
1983-12-22 |
1994-11-15 |
Elan Corporation, Plc |
Controlled absorption diltiazem formulation for once daily administration
|
|
US5023252A
(en)
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US4992445A
(en)
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
US5001139A
(en)
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
US4902514A
(en)
|
1988-07-21 |
1990-02-20 |
Alza Corporation |
Dosage form for administering nilvadipine for treating cardiovascular symptoms
|
|
DE19929076A1
(de)
|
1999-06-25 |
2000-12-28 |
Aventis Pharma Gmbh |
Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
|
TWI243164B
(en)
|
2001-02-13 |
2005-11-11 |
Aventis Pharma Gmbh |
Acylated indanyl amines and their use as pharmaceuticals
|
|
GB0127547D0
(en)
|
2001-11-16 |
2002-01-09 |
Astrazeneca Ab |
Chemical compounds
|
|
TW200301698A
(en)
|
2001-12-21 |
2003-07-16 |
Bristol Myers Squibb Co |
Acridone inhibitors of IMPDH enzyme
|
|
US6995144B2
(en)
*
|
2002-03-14 |
2006-02-07 |
Eisai Co., Ltd. |
Nitrogen containing heterocyclic compounds and medicines containing the same
|
|
JP2005060255A
(ja)
|
2003-08-20 |
2005-03-10 |
Nippon Nohyaku Co Ltd |
カルボキサミド類及びこれを有効成分とする有害生物防除剤
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
KR20070030196A
(ko)
*
|
2004-04-13 |
2007-03-15 |
이카겐, 인코포레이티드 |
칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
|
|
EP2044061A2
(en)
|
2006-07-20 |
2009-04-08 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
|
US20080269241A1
(en)
|
2007-02-15 |
2008-10-30 |
Darin Allen |
Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
|
|
US8445686B2
(en)
*
|
2007-08-27 |
2013-05-21 |
Abbvie Inc. |
4-(4-pyridinyl)-benzamides and their use as rock activity modulators
|
|
US9321727B2
(en)
|
2011-06-10 |
2016-04-26 |
Hoffmann-La Roche Inc. |
Pyridine derivatives as agonists of the CB2 receptor
|
|
EP2970240B1
(en)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
NZ725860A
(en)
*
|
2014-04-04 |
2019-08-30 |
Iomet Pharma Ltd |
Indole derivatives for use in medicine
|
|
TW201642855A
(zh)
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
EP3275440B1
(en)
|
2015-03-25 |
2022-05-04 |
National Center for Geriatrics and Gerontology |
Novel oxadiazole derivative and pharmaceutical containing same
|
|
JPWO2017170826A1
(ja)
|
2016-03-30 |
2019-02-14 |
味の素株式会社 |
グルカゴン様ペプチド−１受容体作用増強活性を有する化合物
|
|
WO2018187480A1
(en)
|
2017-04-04 |
2018-10-11 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
|
CN114364693A
(zh)
|
2019-05-03 |
2022-04-15 |
新加坡保健服务私人有限公司 |
代谢性疾病的治疗和预防
|
|
KR20220016086A
(ko)
|
2019-05-03 |
2022-02-08 |
프락시스 프리시젼 메디신즈, 인크. |
Kcnt1 억제제 및 사용 방법
|
|
KR20250172745A
(ko)
|
2019-05-03 |
2025-12-09 |
프락시스 프리시젼 메디신즈, 인크. |
Kcnt1 억제제 및 사용 방법
|
|
KR20230005168A
(ko)
|
2020-03-23 |
2023-01-09 |
프락시스 프리시젼 메디신즈, 인크. |
Kcnt1 억제제 및 사용 방법
|
|
CA3188825A1
(en)
|
2020-07-06 |
2022-01-13 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
|
WO2022140547A2
(en)
|
2020-12-22 |
2022-06-30 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
|
EP4329735B1
(en)
|
2021-04-29 |
2026-02-25 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
|
US20250360117A1
(en)
|
2022-06-08 |
2025-11-27 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
|